Early diagnosis of rare kidney diseases has profound implications for patients in terms of access to treatment, disease trajectory and the identification of affected relatives. The innovative and collaborative approach taken by the global Alport community has delivered a sustainable global network that has advanced treatments and knowledge and offers insights that are relevant to the entire nephrology community.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Wong, K. et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet 403, 1279–1289 (2024).
Gross, O. et al. Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients. ISRN Pediatr. 2012, 436046 (2012).
Temme, J. et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 81, 779–783 (2012).
Miner, J. H. et al. The 2014 International Workshop on Alport Syndrome. Kidney Int. 86, 679–684 (2014).
Gibson, J. et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J. Am. Soc. Nephrol. 32, 2273–2290 (2021).
Acknowledgements
I would like to acknowledge people living with rare kidney diseases around the world who are engaged in and inspiring research and leading their national patient organizations; the Trustees and team at Alport UK; the Alport Syndrome Alliance Workshop Organizing Committee members for 12 years of collaboration, for contributing to the international workshops on Alport Syndrome and for shared projects that are advancing treatments and knowledge.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Gear, S. Working together to diagnose rare kidney disease earlier. Nat Rev Nephrol (2026). https://doi.org/10.1038/s41581-026-01069-x
Published:
Version of record:
DOI: https://doi.org/10.1038/s41581-026-01069-x
